Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$16.61NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/29/20

Today's Change-0.39(2.29%)
Bid (Size)$16.74 (1)
Ask (Size)$17.00 (1)
Day Low / High$15.95 - 16.95

View Biotechnology IndustryPeer Comparison as of 05/29/2020


Aimmune Therapeutics Inc ( NASDAQ )

Price: $16.61
Change: -0.39 (2.29%)
Volume: 146.00
4:00PM ET 5/29/2020

Myriad Genetics Inc ( NASDAQ )

Price: $14.53
Change: +0.12 (0.83%)
Volume: 1.2 M
3:59PM ET 5/29/2020

Sorrento Therapeutics Inc ( NASDAQ )

Price: $5.05
Change: +0.10 (2.02%)
Volume: 17.9 K
3:59PM ET 5/29/2020

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Rocket Pharmaceuticals Inc ( NASDAQ )

Price: $18.81
Change: -0.07 (0.37%)
Volume: 200.00
3:59PM ET 5/29/2020

Read more news Recent News

Analyst Actions: Credit Suisse Cuts Aimmune Therapeutics PT to $19 From $29 as Palforzia Launch on Hold Due to COVID-19, Maintains Neutral Rating
9:55AM ET 5/13/2020 MT Newswires

Aimmune Therapeutics' (AIMT) average rating among analysts is a buy, with an average price target of $41. Price: 16.92, Change: -0.09, Percent Change:...

--Analyst Actions: RBC Cuts Price Target on Aimmune Therapeutics to $52 From $54 on Delayed Palforzia Launch in the US; Maintains Outperform/Speculative Risk
10:10AM ET 5/12/2020 MT Newswires

Price: 17.41, Change: -0.49, Percent Change: -2.74 ...

Insider Trends: Insider Buying Continued with Purchase of AIMSI Technologies Stock
4:48PM ET 4/24/2020 MT Newswires

Nestle Health Science US Holdings, Inc., 10% Owner, on Feb 26, 2018, made a purchase of 4,175,029 shares in AIMSI Technologies (AIMT) for $128,000,003. ...

Insider Trends: Aimmune Therapeutics Insider 90-Day Buying Trend Prolonged with Purchase
4:48PM ET 4/24/2020 MT Newswires

Nestle Health Science US Holdings, Inc., 10% Owner, purchased 4,175,029 shares in Aimmune Therapeutics (AIMT) for $128,000,003 on Feb 26, 2018. Nestle...

Company Profile

Business DescriptionAimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. View company web site for more details
Address8000 Marina Boulevard
Brisbane, California 94005-1884
Number of Employees215
Recent SEC Filing05/29/20204
President, Chief Executive Officer & DirectorJayson Donald Alexander Dallas
Chief Financial OfficerEric Hands Claude Bjerkholt
Chief Medical OfficerDaniel C. Adelman
Vice President-Clinical OperationsAnnette Marcantonio

Company Highlights

Price Open$16.93
Previous Close$16.61
52 Week Range$10.09 - 37.00
Market Capitalization$1.1 B
Shares Outstanding65.3 M
SectorHealth Technology
Next Earnings Announcement08/13/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.44
Beta vs. S&P 500N/A
Net Profit Margin-48,810.96%
Return on Equity-161.13%

Analyst Ratings as of 03/17/2020

Consensus RecommendationConsensus Icon
Powered by Factset